This is a knockout-validated antibody summary, based on the publication "p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Mouse monoclonal IgG1k

Company: Active Motif

Antibody: Tet2

Catalog number: 61389

Summary: Mouse monoclonal IgG1k against a recombinant protein corresponding to amino acids 1-300 of human Tet2. Reacts with human by western blot and immunoprecipitation.

Western blot

WT and p53KO HCT116 cells. Cells were lysed on ice by using RIPA lysis buffer (50mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150mM NaCl, 2mM EDTA, 50Mm NaF) supplemented with protease inhibitor and phosphatase inhibitor cocktail (Gendeport, Barker, TX, USA).

5% non-fat milk in Tris-buffered saline pH 7.6 containing 0.1% Tween-20.

Overnight at 4°C.

1:3,000 dilution anti-mouse secondary antibody (Cell Signaling Technology, Cat# 7076) for 1 h at room temperature.

The antigen–antibody complexes were detected using West-Q Pico Dura ECL Solution (Gendeport, Barker, TX, USA).

TET2 and p53 protein expression levels in WT and p53KO HCT116 cells treated with and without sgRNA to deplete endogenous TET2. Please see Figure 1b in the article [1].